Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - Ανοσοκατασταλτικά - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - Ανοσοκατασταλτικά - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 και 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 και 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

krka d.d., novo mesto, slovenia (0000005093) smarkeska cesta 6,, 8501 novo mest - montelukast sodium - ΜΑΣΩΜΕΝΟ ΔΙΣΚΙΟ - 4mg/tab - ineof01106 montelukast sodium 4.160000 mg - montelukast

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

krka d.d., novo mesto, slovenia (0000005093) smarkeska cesta 6,, 8501 novo mest - montelukast sodium - ΜΑΣΩΜΕΝΟ ΔΙΣΚΙΟ - 5mg/tab - ineof01106 montelukast sodium 5.200000 mg - montelukast

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

krka d.d., novo mesto, slovenia (0000005093) smarkeska cesta 6,, 8501 novo mest - montelukast sodium - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 10mg/tab - ineof01106 montelukast sodium 10.400000 mg - montelukast

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

krka d.d., novo mesto, slovenia (0000005093) smarkeska cesta 6,, 8501 novo mest - atorvastatin - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 30mg/tab - 0134523005 atorvastatin 30.000000 mg - atorvastatin

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

krka d.d., novo mesto, slovenia (0000005093) smarkeska cesta 6,, 8501 novo mest - atorvastatin - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 60mg/tab - 0134523005 atorvastatin 60.000000 mg - atorvastatin

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

krka d.d., novo mesto, slovenia (0000005093) smarkeska cesta 6,, 8501 novo mest - atorvastatin - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 80mg/tab - 0134523005 atorvastatin 80.000000 mg - atorvastatin

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

krka d.d., novo mesto, slovenia (0000005093) smarkeska cesta 6,, 8501 novo mest - valsartan; hydrochlorothiazide - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - (320+25)mg/tab - 0137862534 valsartan 320.000000 mg; 0000058935 hydrochlorothiazide 25.000000 mg - valsartan and diuretics

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

krka d.d., novo mesto, slovenia (0000005093) smarkeska cesta 6,, 8501 novo mest - valsartan; hydrochlorothiazide - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - (320+12,5)mg/tab - 0137862534 valsartan 320.000000 mg; 0000058935 hydrochlorothiazide 12.500000 mg - valsartan and diuretics